Friday, May 15, 2020 6:26:20 PM
The company said that they were researching billions of antibodies and discovered about a dozen that were capable of blocking the spike proteins that the coronavirus uses to attach to human enzymes. Out of those antibodies, they found one, STI-1499, that had a one hundred percent success rate.
"When the antibody prevents a virus from entering a human cell, the virus cannot survive," Dr. Henry Ji, founder and CEO of Sorrento Therapeutics, told Fox News. "If they cannot get into the cell, they cannot replicate. So it means that if we prevent the virus from getting the cell, the virus eventually dies out. The body clears out that virus."
The company is planning to begin testing on animals soon and hopes to start clinical trials by July. If everything goes well, Sorrento Therapeutics believes their treatment could allow the world to ease up on social distancing long before a vaccine is ready.
"We want to emphasize there is a cure. There is a solution that works 100 percent," Dr. Ji said. "If we have the neutralizing antibody in your body, you don't need the social distancing. You can open up a society without fear."
https://woodradio.iheart.com/content/2020-05-15-biopharmaceutical-company-claims-they-discovered-treatment-for-covid-19/
Stingrays fall into two general categories, bottom feeders and swimmers...um hungry
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM